This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session. (HOTAIR2)

This study has been completed.
Information provided by (Responsible Party):
A/Prof Leonie Heilbronn, University of Adelaide Identifier:
First received: December 9, 2013
Last updated: November 30, 2015
Last verified: November 2015
Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have recently shown that exposure to hyperbaric oxygen (HBO) leads to an increase insulin sensitivity in males ubjects and that this improvement can be measured in all men, not just those with diabetes. The aim of this study is to investigate the time course of this effect and explore the mechanisms involved. The investigators suspect that insulin sensitivity as measured by hyperinsulinaemic-euglycaemic clamp will be increased within the time-frame of one 2-hour hyperbaric oxygen exposure, and that the improvement will be measurable in females as well as males.

Condition Intervention
Obesity Type 2 Diabetes Procedure: Hyperbaric Oxygen Therapy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.

Resource links provided by NLM:

Further study details as provided by A/Prof Leonie Heilbronn, University of Adelaide:

Primary Outcome Measures:
  • Insulin sensitivity [ Time Frame: 2 hours ]

Secondary Outcome Measures:
  • Hypoxia and inflammatory markers [ Time Frame: 2 hours ]
    Using immuno-histo chemistry (IHC), quantitative plymerase chain reaction (qPCR), Western blot

Enrollment: 9
Study Start Date: March 2013
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Hyperbaric Oxygen Therapy
    Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Overweight to obese (BMI 25-35 kg/m2)
  • Age >18 years (no specific upper age limit)
  • Fit to enter hyperbaric chamber as assessed by hyperbaric physician.

Exclusion Criteria:

  • Personal history of Diabetes
  • Personal history of major psychiatric disorders
  • UIse of prescribed or non-prescribed medications which may affect glucose homeostasis (e.g. steroids),
  • Uncontrolled asthma,
  • Current fever or upper respiratory infections
  • Individuals who regularly perform high intensity exercise (>2 week),
  • Pregnancy, lactation and women who are planning to become pregnant
  • Current intake of >140g alcohol/week,
  • Current smokers of cigarettes/cigars/marijuana,
  • Current inatke of any illicit substance,
  • Claustrophobia
  • has donated blood within past 3 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02009813

Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
University of Adelaide
Principal Investigator: Leonie K Heilbronn, PhD University of Adelaide
Principal Investigator: David Wilkinson, BMBS University of Adelaide
  More Information

Responsible Party: A/Prof Leonie Heilbronn, A/Prof, University of Adelaide Identifier: NCT02009813     History of Changes
Other Study ID Numbers: RAH121212a
Study First Received: December 9, 2013
Last Updated: November 30, 2015

Keywords provided by A/Prof Leonie Heilbronn, University of Adelaide:
Insulin resistance

Additional relevant MeSH terms:
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017